Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VC005
Therapeutic Area : Dermatology
Study Phase : Phase III
Recipient : JIANGSU VCARE PHARMATECH CO., LTD
Deal Size : Undisclosed
Deal Type : Partnership
Vcare Enters into Partnership with Huadong Medicine to Commercialize VC005 in China
Details : The partnership aims to commercialize VC005 tablets, a second-generation, highly selective JAK1 inhibitor currently in Phase III trials for moderate-to-severe atopic dermatitis, in mainland China.
Product Name : VC005
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 16, 2025
Lead Product(s) : VC005
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Recipient : JIANGSU VCARE PHARMATECH CO., LTD
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : SNK-2726
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : SynerK PharmaTech
Deal Size : Undisclosed
Deal Type : Collaboration
Huadong and SynerK Partner to Develop siRNA Drug SNK-2726 for Novel Applications
Details : Through the collaboration, the two parties will jointly develop the small nucleic acid (siRNA) drug SNK-2726, which targets angiotensinogen (AGT) for the treatment of hypertension.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
December 30, 2024
Lead Product(s) : SNK-2726
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : SynerK PharmaTech
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : HDM1002
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUADONG MEDICINE Reports Positive Phase I Results for GLP-1 Agonist HDM1002
Details : HDM1002 is an innovative potent small molecule drug, highly selective full agonist of the GLP-1 receptor. It is being developed for Type 2 Diabetes Mellitus.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 26, 2024
Lead Product(s) : HDM1002
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Insilico Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will leverage Huadong Medicine's advanced innovative drug discovery and screening characterization platform, in combination with Insilico's end-to-end AI-driven drug discovery platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 09, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Insilico Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Exscientia
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under this collaboration, Exscientia will use its advanced Centaur Chemist AI platform to design new molecules against project specific targets and Huadong will apply its experimental and managerial capabilities to support Exscientia’s AI design in a r...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 09, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Exscientia
Deal Size : Undisclosed
Deal Type : Partnership